Contact us

For France: Ulysse Communication

Bruno Arabian

For Belgium - Comfi

Laure-Eve Monfort

Celyad

Filippo Petti, Chief Financial Officer, investors@celyad.com; Anne Moore, Vice President Corporate Srategy, Communications@celyad.com

For the U.S.: LifeSci Investor Relations

Daniel Ferry – T.: +1 (617) 535 7746 – daniel@lifesciadvisors.com, Public Relations: Sara Zelkovic – T:+1 (646) 876 4933 - sara@lifescipublicrelations.com

Get updates in your mailbox

By clicking "Subscribe" I confirm I have read and agree to the Privacy Policy.

About Celyad

About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the NASDAQ Global Market, all under the ticker symbol CYAD. 

Contact

Mont-Saint-Guibert (BELGIUM) Axis Business Park Rue Edouard Belin 2 1435 Mont-Saint-Guibert Belgium

+32(0) 10 39 41 00

investors@celyad.com

www.celyad.com